Canada Pension Plan Investment Board trimmed its holdings in shares of Alkermes PLC (NASDAQ:ALKS) by 41.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,358 shares of the company’s stock after selling 56,200 shares during the quarter. Canada Pension Plan Investment Board owned 0.05% of Alkermes PLC worth $4,035,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in ALKS. Greenwood Capital Associates LLC grew its stake in Alkermes PLC by 1.1% during the 2nd quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock valued at $219,000 after purchasing an additional 41 shares during the last quarter. World Asset Management Inc grew its stake in Alkermes PLC by 1.9% during the 2nd quarter. World Asset Management Inc now owns 6,939 shares of the company’s stock valued at $402,000 after purchasing an additional 128 shares during the last quarter. Capstone Asset Management Co. grew its stake in Alkermes PLC by 2.6% during the 2nd quarter. Capstone Asset Management Co. now owns 6,755 shares of the company’s stock valued at $392,000 after purchasing an additional 170 shares during the last quarter. M&T Bank Corp grew its stake in Alkermes PLC by 2.9% during the 2nd quarter. M&T Bank Corp now owns 7,135 shares of the company’s stock valued at $413,000 after purchasing an additional 200 shares during the last quarter. Finally, Toronto Dominion Bank grew its stake in Alkermes PLC by 12.7% during the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after purchasing an additional 212 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/11/16/canada-pension-plan-investment-board-sells-56200-shares-of-alkermes-plc-alks.html.

Several research firms have weighed in on ALKS. J P Morgan Chase & Co set a $78.00 price target on Alkermes PLC and gave the company a “buy” rating in a research note on Friday, October 27th. UBS AG set a $54.00 target price on Alkermes PLC and gave the stock a “hold” rating in a research note on Friday, October 27th. Credit Suisse Group lowered their target price on Alkermes PLC from $70.00 to $66.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Barclays PLC set a $50.00 target price on Alkermes PLC and gave the stock a “hold” rating in a research note on Thursday, October 26th. Finally, Citigroup Inc. set a $62.00 target price on Alkermes PLC and gave the stock a “hold” rating in a research note on Thursday, October 26th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $63.55.

In related news, Director Richard F. Pops sold 50,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $48.87, for a total value of $2,443,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $50.77, for a total value of $76,155.00. Following the completion of the transaction, the director now owns 9,500 shares of the company’s stock, valued at $482,315. The disclosure for this sale can be found here. Insiders sold 102,498 shares of company stock valued at $5,018,010 over the last 90 days. Company insiders own 5.34% of the company’s stock.

Alkermes PLC (NASDAQ ALKS) opened at $48.08 on Thursday. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes PLC has a fifty-two week low of $46.42 and a fifty-two week high of $63.40.

Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.04. The business had revenue of $217.40 million during the quarter, compared to analyst estimates of $231.29 million. Alkermes PLC had a negative return on equity of 7.27% and a negative net margin of 20.12%. The business’s revenue was up 20.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.09) earnings per share. equities research analysts anticipate that Alkermes PLC will post -0.59 earnings per share for the current fiscal year.

Alkermes PLC Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.